A rapid, reversed-phase liquid chromatographic method was developed for the assay of nystatin in the bulk drug and a variety of dosage forms. Analysis was performed on a Symmetry C 18 reversed-phase column using a mobile phase of methanol-water-dimethylformamide (DMF; 55 + 30 + 15, v/v/v), with detection by UV at 305 nm. Quantitation is based on the sum of the peak areas of the 2 major isomers of nystatin. The linearity of the assay was determined for a concentration range of 0.05 to 0.2 mg/mL (correlation coefficient > 0.999). Accuracies and precision showed good reproducibility.
N ystatin, also known as mycostatin, is a member of a class of antifungal antibiotics used to treat yeasts and yeast-like fungal infections. It is prescribed for treatment of superficial oral and intestinal infections caused by Candida species. This group is commonly referred to as polyene macrolide antifungal antibiotics because they are comprised of a macrocyclic ring of carbon atoms closed by lactonization and contain a series of conjugated carbon double bonds. Nystatin (C 47 H 75 NO 17 ; mol. wt. 926.13) contains a diene and hydroxylated tetraene moiety attached to mycosamine (Figure 1; 1, 2) .
Commercially available nystatin can be a mixture of 2 or more biologically active components of which nystatin A1 is the most common (3, 4) . The official method for premarket certification of nystatin is by microbial assay as outlined in the U.S. Pharmacopeia (USP; 3). Potency is measured in terms of USP nystatin units. There are no regulatory requirements to determine the amount of each component. Microbial methods measure the total activity of substances responding to a particular organism and therefore, lack the selectivity that can be achieved by a liquid chromatographic (LC) method. In addition, the microbial assay for nystatin has been found to be time-consuming. This report describes the development of a rapid LC method for assay of nystatin in a variety of pharmaceutical samples and is proposed as an alternative to the current microbial method.
Several authors have described reversed-phase LC methods for the analysis and purification of nystatin (2, 5, 6 , and references cited therein). Due to the known instability of nystatin at low pH (4), a neutral mobile phase was used in the present study. Under neutral conditions, using a mobile phase composed of methanol-water-DMF, Sauer and Matusch (2) have separated nystatin by LC into 5 components, consisting of the main fraction (nystatin A1) and a late eluting fraction (identified as an heptaene impurity). The major focus of their study was the purification of nystatin in order to obtain sufficient quantities for testing antifugal activity. To obtain greater resolution and improved peak shapes to allow for quantitation of nystatin, their method was modified in the present study, by changing the column and adjusting the mobile phase composition. Under the modified conditions described in this paper, these objectives were achieved and in addition, the number of peaks and their elution order were unaffected. The mobile phase had an apparent pH of 6.7. The modified method was validated for precision, accuracy, and linearity. It was successfully applied to the assay of the bulk drug and a variety of dosage forms. Assay results were compared with those obtained with the USP microbial method. (1) 2 single piston pumps (LC-600), autoinjector (Sil-6B), system controller (SCL-6B), UV detector (SPD-6A), data processor (Chromatopac C-R4A); (2) 2 single piston pumps (LC-6A), autoinjector (Sil-6B), system controller (SCL-6B), UV-VIS detector (SPD-6AV), data processor (Chromatopac C-R4AX); (3) one pump (LC-10AS), autoinjector (Sil-10A), system controller (SCL-10A), UV-VIS detector (SPD-10A), EZChrom data system; (4) as for (3), except, 2 pumps (LC-10AS), and UV-VIS detector (SPD-10AV); (5) 2 pumps (LC-10ATVP), degasser (DGU-14A), autoinjector (SIL-10A), UV-VIS detector (SPD-10AVP), system controller (SCL-10AVP), Class VP data system.
METHOD

Reagents and Materials
Standard Preparation
Notes: (1) The weights and volumes listed below were used when the assay was run at the test concentration of 548 nystatin units/mL. When the assays were run at 80 and 120% of the test concentration (438 and 658 nystatin units/mL, respectively), the appropriate adjustments in weights and dilutions were made.
(2) Low actinic glassware should be used in order to protect the nystatin solutions from exposure to light.
Accurately weigh 5.0 mg of the standard (standard used was USP lot N, 5480 nystatin units/mg) and transfer to a 50.0 mL volumetric flask. Dissolve in ca 48 mL mobile phase by sonicating for 2 min. Dilute to volume with the mobile phase and shake. The test concentration is 548 nystatin units/mL.
Sample Preparations
Note: Sample preparations are best used within 24 h. (a) Bulk drug.-The bulk drug is prepared as described for the standard solution.
(b) Topical powder.-The container is shaken, or the contents stirred with a spatula before sampling. Weigh an amount of powder equivalent to ca 13 750 nystatin units (137.5 mg, where label claim is 100 000 units/g) and transfer to a 25.0 mL volumetric flask, add 20 mL mobile phase and sonicate for 3-5 min. Shake for 10 min, dilute to volume with the mobile phase, and shake manually ca 2 min. Centrifuge ca 10 min, then filter using a Gelman Arcodisc PTFE or GHP (0.45 µm) syringe filter.
(c) Oral suspensions.-The container is shaken for ca 30 s and allowed to sit for 30 s before sampling. Using a "to contain" pipet, transfer a volume equivalent to 100 000 units (1.0 mL, where label claim is 100 000 units/mL) to a 200.0 mL volumetric flask. Rinse the contents of the pipet with 10 mL mobile phase into the volumetric flask. After mobile phase is added to bring the volume to ca 190 mL, sonicate 5 min, and shake 10 min, then dilute to volume with the mobile phase.
(d) Tablets.-The tablets were assayed individually, because of the difficulty experienced in compositing the coated tablets. Weigh 20 tablets and determine the average tablet weight. Weigh one tablet (label claim, 500 000 nystatin units/tablet) and transfer to a 250.0 mL volumetric flask, add Cream.-Into a 50.0 mL volumetric flask, weigh an amount of cream equivalent to 27 400 nystatin units (274.0 mg, where label claim is 100 000 units/g). Add 10 mL DMF followed by 30 mL methanol (previously heated on a steam bath). Sonicate 10 min, shake 15 min, and add water to bring the volume to ca 48 mL (slightly exothermic), then shake manually. Allow the mixture to cool to room temperature, dilute to volume with water, and shake. Filter as described for the topical powder.
(f) Ointment.-Into a 50 mL centrifuge tube, weigh an amount of ointment equivalent to 27 400 nystatin units (274 mg, where the label claim is 100 000 units/g). Add 10.0 mL DMF and mix on Vortex mixer for 2-3 min until the ointment becomes clear. Decant the solution and dilute 2.0 mL to 10.0 mL with the diluent (methanol-water, 70 + 35, v/v). Syringe filter as described for the topical powder.
Determination
With the detector set at 305 nm, the column at ambient temperature, and the mobile phase flowing at 1.0 mL/min, the LC system is equilibrated until a stable baseline is obtained. The flow rate is set at 0.8 mL/min, when the 150 mm column is used. Five replicate injections (20 µL) of the standard solution are made and the sum of the areas of the 2 nystatin peaks are recorded. On the 250 mm column, mean retention times for the 2 nystatin peaks are 11.7 (major peak) and 17.5 min (minor peak), relative retention time ca 1.5 ( Figure 2) . In a suitable system, the coefficient of variation (CV) is ≤2%. Duplicate injections (20 µL) of the sample solutions are made with bracketing standard injection. Following use with the mobile phase, the column is washed with 50% methanol-water followed by methanol for ca 1 h for each wash, at a flow rate of 1.0 mL/min.
Calculations
Calculate the number of (nystatin units)/weight or volume of sample as follows: where Rs and Ru are the sum of the nystatin peak areas in the standard and sample solutions, respectively, and the sample weights are as follows:
(1) Ointment, cream, topical powder -sample wt (g) (2) Bulk drug -sample wt (mg) (3) Oral suspension -substitute sample vol (mL) for sample wt (4) Tablets -sample wt = tablet wt (g)/avg tablet wt (g)
Microbial Assay
The bioassay of nystatin was performed according to the procedure outlined in the USP (3). This entails the preparation of a stock solution of the sample in DMF. Stock solutions are diluted with a phosphate buffer of pH 6.0 ± 0.05 to obtain the test solutions. The inhibitory effect of nystatin on the microorganism is determined by the cylinder-plate assay.
Results and Discussion
Representative chromatograms of nystatin on a Symmetry C 18 , 4.6 × 250 mm column are shown in Figure 2 . The mean retention times of the 2 peaks of nystatin used in quantitation were 11.7 (major peak) and 17.5 min (minor). It is interesting to note that when the standard is injected shortly after preparation, the minor peak is about 3% (area) of the major peak. The area of the major peak decreases, while the minor peak gradually increases to about 20% of the major peak after about 12 h. However, the sum of the area of the 2 peaks remained constant. This would suggest that transformation of the major to minor component is taking place in the solution. When the solution is refrigerated, the rate of formation of the minor peak is reduced. Similar behavior was observed for the bulk drug and pharmaceutical preparations. Plausible explanations are the formation of a hemiketal between the carbonyl group at C-13 and the hydroxyl group at C-17 (1), or that the 2 peaks represent Z/E isomers of the diene. Groll and co-workers (6) also observed 2 nystatin peaks with a mobile phase of pH 6 and used the sum of the peaks in quantitation.
A recent report (7) supports the existence of nystatin in 2 isomeric forms, whose identities were confirmed by mass spectroscopy and nuclear magnetic resonance (NMR). The authors observed that interconversion of the isomers was pH dependent and further investigated the antifungal activity of each isomer. At pH 6.0, the major isomer converts slowly to the less active isomer. The rate is accelerated at pH >7.0. These observations have important implications for analytical procedures. Solvent systems with pH values maintained at 6.0 or be- Table 6 . Assay results for nystatin ointment (declared 100 000 units/g)
